Anti-PD-(L)1 for KRAS-mutant advanced non-small –cell lung cancers: a meta-analysis of randomized–controlled trials
ConclusionsAnti-PD-(L)1 with or without chemotherapy seemed to achieve longer OS and PFS than chemotherapy alone for patients withKRAS-mutant and wild-typeKRAS advanced NSCLCs, with an even greater OS benefit for the former.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Sarcomas